{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-25-000059","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.526998+00:00","generated_at":"2026-05-22T04:59:26.784408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%","bullets":["Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.","Cash, cash equivalents, and marketable securities $54.5M; runway into 1H 2027.","RLYB212 program discontinued after Phase 2 PK data missed target concentrations.","Workforce reduction of 40% (nine positions) with ~$1.7M in severance charges; substantially complete by end of Q2 2025.","RLYB116 confirmatory PK/PD study on track to start in Q2 2025; Cohort 1 data in Q3, Cohort 2 in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-25-000059","json":"https://secwatch.observer/filing/0001739410-25-000059.json","markdown":"https://secwatch.observer/filing/0001739410-25-000059.md","text":"https://secwatch.observer/filing/0001739410-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/0001739410-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/rlyb-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:59:26.784408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}